Skip to main content

Consecutive oral administration of Bifidobacterium longum MM‐2 improves the defense system against influenza virus infection by enhancing natural killer cell activity in a murine model

  • 2015-01
  • Microbiology and Immunology 59(1)
    • Tomohiro Kawahara
    • Tadanobu Takahashi
    • Kenta Oishi
    • Hiromu Tanaka
    • M. Masuda
    • Shunsaku Takahashi
    • Maiko Takano
    • Tatsuya Kawakami
    • Keijo Fukushima
    • H. Kanazawa
    • Takashi Suzuki

Abstract

Bifidobacterium, one of the major components of intestinal microflora, shows anti-influenza virus (IFV) potential as a probiotic, partly through enhancement of innate immunity by modulation of the intestinal immune system. Bifidobacterium longum MM-2 (MM-2), a very safe bacterium in humans, was isolated from healthy humans and its protective effect against IFV infection in a murine model shown. In mice that were intranasally inoculated with IFV, oral administration of MM-2 for 17 consecutive days improved clinical symptoms, reduced mortality, suppressed inflammation in the lower respiratory tract, and decreased virus titers, cell death, and pro-inflammatory cytokines such as IL-6 and TNF-α in bronchoalveolar lavage fluid. The anti-IFV mechanism of MM-2 involves innate immunity through significant increases in NK cell activities in the lungs and spleen and a significant increase in pulmonary gene expression of NK cell activators such as IFN-γ, IL-2, IL-12 and IL-18. Even in non-infected mice, MM-2 administration also induced significant enhancement of both IFN-γ production by Peyer's patch cells (PPs) and splenetic NK cell activity. Oral administration of MM-2 for 17 days activates systemic immunoreactivity in PPs, which contributes to innate immunity, including NK cell activation, resulting in an anti-IFV effect. MM-2 as a probiotic may function as a prophylactic agent in the management of an IFV epidemic.

Keywords: Bifidobacterium longum; influenza virus; natural killer cell; probiotics.

Research Insights

SupplementHealth OutcomeEffect TypeEffect Size
Bifidobacterium longum MM-2Activated Systemic Immunoreactivity in Peyer's PatchesBeneficial
Moderate
Bifidobacterium longum MM-2Enhanced IFN-γ ProductionBeneficial
Moderate
Bifidobacterium longum MM-2Improved Clinical Symptoms of InfluenzaBeneficial
Large
Bifidobacterium longum MM-2Improved Splenetic NK Cell ActivityBeneficial
Moderate
Bifidobacterium longum MM-2Increased Pulmonary NK Cell Activator Gene ExpressionBeneficial
Large
Bifidobacterium longum MM-2Reduced Inflammation in the Lower Respiratory TractBeneficial
Large
Bifidobacterium longum MM-2Reduced Mortality from Influenza InfectionBeneficial
Large
Bifidobacterium longum MM-2Reduced Virus Titers in Bronchoalveolar Lavage FluidBeneficial
Large

Pillser helps you make informed health decisions by providing comprehensive, unbiased information about supplements. This includes detailed research on supplement ingredients, their benefits, potential risks, and their overall efficacy. You can contribute by sharing your feedback and suggestions.

Send us an email at support@pillser.com.